INTRODUCING MARC: A REVOLUTION IN CELL THERAPY.
Our proprietary Modular Actuation Receptor Cells (MARC) harness the natural architecture of immune receptors to create a superior immunotherapy against cancer and autoimmune diseases
- Modular complex with separate targeting and signaling modules
- Powerful signaling fully activate cells
- ON when triggered but OFF when recycled
- Single signal output
- Single component with connected targeting and signaling domains
- Weak signal prevents full engagement of cell response
- Always ON (tonic signal) causes cell exhaustion and toxicity
- Modular complex with separate targeting and signaling modules
- Powerful signaling fully activates cells
- ON when triggered but OFF when recycled
- Multi-signal output
The MARC technology profile delivers the solution.
Complex and logic-gated
Modular receptors allow us to engineer bespoke signalling outputs to direct desired cell behaviors (ex: proliferation, survival, memory, activation). This unique technology provides an enhanced and sustained immune response, specific to the disease in question.
Immune cell-agnostic
MARC technology is proven to work with many immune cell types, including but not limited to: T cells, NK cells, macrophages, monocytes, and dendritic cells.
Compatible with iPSCs/stem cells
MARC expressing stem cells/iPSCs can effectively differentiate to recreate the entire immune system and produce a full range of anti-cancer responses.
Safer and more persistent
MARC-T cells release significantly less of the cytokines classically associated with CAR-T cell toxicity. Moreover, MARC-T cells shown far less cell exhaustion and can therefore provide a sustained response to effectively cure cancer and prevent relapse.
Investors & Partners
